#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-9	Cognitive	_
1-2	10-17	control	_
1-3	18-25	network	_
1-4	26-41	dysconnectivity	_
1-5	42-45	and	_
1-6	46-54	response	_
1-7	55-57	to	_
1-8	58-71	antipsychotic	_
1-9	72-81	treatment	_
1-10	82-84	in	_
1-11	85-98	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-12	99-101	To	_
1-13	102-108	better	_
1-14	109-119	understand	_
1-15	120-129	cognitive	_
1-16	130-137	control	_
1-17	138-148	impairment	_
1-18	149-151	in	_
1-19	152-165	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-20	166-167	,	_
1-21	168-170	it	_
1-22	171-173	is	_
1-23	174-179	vital	_
1-24	180-182	to	_
1-25	183-192	determine	_
1-26	193-196	the	_
1-27	197-203	extent	_
1-28	204-206	of	_
1-29	207-220	dysfunctional	_
1-30	221-233	connectivity	_
1-31	234-236	in	_
1-32	237-240	the	_
1-33	241-251	associated	_
1-34	252-267	fronto-striatal	_
1-35	268-273	brain	_
1-36	274-281	network	_
1-37	282-283	,	_
1-38	284-288	with	_
1-39	289-290	a	_
1-40	291-296	focus	_
1-41	297-299	on	_
1-42	300-303	the	_
1-43	304-315	connections	_
1-44	316-320	with	_
1-45	321-324	the	_
1-46	325-333	anterior	_
1-47	334-343	cingulate	_
1-48	344-350	cortex	_
1-49	351-352	(	_
1-50	353-356	ACC	_
1-51	357-358	)	_
1-52	359-360	,	_
1-53	361-366	prior	_
1-54	367-369	to	_
1-55	370-373	the	_
1-56	374-383	potential	_
1-57	384-395	confounding	_
1-58	396-402	effect	_
1-59	403-405	of	_
1-60	406-416	medication	_
1-61	417-418	.	_

2-1	419-421	It	_
2-2	422-424	is	_
2-3	425-429	also	_
2-4	430-439	essential	_
2-5	440-442	to	_
2-6	443-452	determine	_
2-7	453-456	the	_
2-8	457-464	effects	_
2-9	465-474	following	_
2-10	475-488	antipsychotic	_
2-11	489-499	medication	_
2-12	500-503	and	_
2-13	504-507	the	_
2-14	508-520	relationship	_
2-15	521-523	of	_
2-16	524-529	those	_
2-17	530-537	effects	_
2-18	538-540	on	_
2-19	541-550	psychosis	_
2-20	551-562	improvement	_
2-21	563-564	.	_

3-1	565-575	Twenty-two	_
3-2	576-584	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-3	585-589	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-4	590-603	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-5	604-605	,	_
3-6	606-615	initially	_
3-7	616-627	unmedicated	_
3-8	628-631	and	_
3-9	632-637	after	_
3-10	638-639	a	_
3-11	640-646	6-week	_
3-12	647-653	course	_
3-13	654-656	of	_
3-14	657-668	risperidone	_
3-15	669-670	,	_
3-16	671-674	and	_
3-17	675-677	20	_
3-18	678-685	matched	_
3-19	686-693	healthy	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
3-20	694-702	controls	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
3-21	703-704	(	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
3-22	705-707	HC	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
3-23	708-709	)	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
3-24	710-719	performed	_
3-25	720-721	a	_
3-26	722-726	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
3-27	727-731	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
3-28	732-737	twice	_
3-29	738-739	,	_
3-30	740-743	six	_
3-31	744-749	weeks	_
3-32	750-755	apart	_
3-33	756-757	.	_

4-1	758-760	We	_
4-2	761-773	investigated	_
4-3	774-779	group	_
4-4	780-783	and	_
4-5	784-796	longitudinal	_
4-6	797-808	differences	_
4-7	809-811	in	_
4-8	812-823	ACC-related	_
4-9	824-834	functional	_
4-10	835-847	connectivity	_
4-11	848-854	during	_
4-12	855-866	performance	_
4-13	867-869	of	_
4-14	870-871	a	_
4-15	872-878	Stroop	_
4-16	879-884	color	_
4-17	885-889	task	_
4-18	890-892	as	_
4-19	893-897	well	_
4-20	898-900	as	_
4-21	901-913	connectivity	_
4-22	914-922	patterns	_
4-23	923-933	associated	_
4-24	934-938	with	_
4-25	939-950	improvement	_
4-26	951-953	in	_
4-27	954-963	psychosis	_
4-28	964-972	symptoms	_
4-29	973-974	.	_

5-1	975-986	Unmedicated	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
5-2	987-995	patients	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
5-3	996-1000	with	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
5-4	1001-1014	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
5-5	1015-1021	showed	_
5-6	1022-1029	greater	_
5-7	1030-1040	functional	_
5-8	1041-1053	connectivity	_
5-9	1054-1061	between	_
5-10	1062-1065	ACC	_
5-11	1066-1069	and	_
5-12	1070-1079	bilateral	_
5-13	1080-1087	caudate	_
5-14	1088-1091	and	_
5-15	1092-1100	midbrain	_
5-16	1101-1104	and	_
5-17	1105-1110	lower	_
5-18	1111-1123	connectivity	_
5-19	1124-1128	with	_
5-20	1129-1133	left	_
5-21	1134-1141	putamen	_
5-22	1142-1150	compared	_
5-23	1151-1153	to	_
5-24	1154-1161	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-25	1162-1170	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-26	1171-1172	.	_

6-1	1173-1175	At	_
6-2	1176-1184	baseline	_
6-3	1185-1186	,	_
6-4	1187-1194	greater	_
6-5	1195-1205	functional	_
6-6	1206-1218	connectivity	_
6-7	1219-1226	between	_
6-8	1227-1230	ACC	_
6-9	1231-1234	and	_
6-10	1235-1244	bilateral	_
6-11	1245-1252	putamen	_
6-12	1253-1262	predicted	_
6-13	1263-1273	subsequent	_
6-14	1274-1280	better	_
6-15	1281-1290	treatment	_
6-16	1291-1299	response	_
6-17	1300-1301	.	_

7-1	1302-1308	Change	_
7-2	1309-1311	in	_
7-3	1312-1322	functional	_
7-4	1323-1335	connectivity	_
7-5	1336-1343	between	_
7-6	1344-1347	ACC	_
7-7	1348-1351	and	_
7-8	1352-1356	left	_
7-9	1357-1364	putamen	_
7-10	1365-1375	positively	_
7-11	1376-1386	correlated	_
7-12	1387-1391	with	_
7-13	1392-1398	better	_
7-14	1399-1408	treatment	_
7-15	1409-1417	response	_
7-16	1418-1419	.	_

8-1	1420-1425	These	_
8-2	1426-1433	results	_
8-3	1434-1441	suggest	_
8-4	1442-1446	that	_
8-5	1447-1455	patterns	_
8-6	1456-1458	of	_
8-7	1459-1469	functional	_
8-8	1470-1482	connectivity	_
8-9	1483-1485	in	_
8-10	1486-1501	fronto-striatal	_
8-11	1502-1510	networks	_
8-12	1511-1514	can	_
8-13	1515-1517	be	_
8-14	1518-1526	utilized	_
8-15	1527-1529	to	_
8-16	1530-1537	predict	_
8-17	1538-1547	potential	_
8-18	1548-1556	response	_
8-19	1557-1559	to	_
8-20	1560-1573	antipsychotic	_
8-21	1574-1584	medication	_
8-22	1585-1586	.	_

9-1	1587-1592	Prior	_
9-2	1593-1595	to	_
9-3	1596-1605	treatment	_
9-4	1606-1607	,	_
9-5	1608-1613	brain	_
9-6	1614-1622	function	_
9-7	1623-1626	may	_
9-8	1627-1629	be	_
9-9	1630-1640	structured	_
9-10	1641-1645	with	_
9-11	1646-1647	a	_
9-12	1648-1662	predisposition	_
9-13	1663-1667	that	_
9-14	1668-1674	favors	_
9-15	1675-1677	or	_
9-16	1678-1681	not	_
9-17	1682-1691	treatment	_
9-18	1692-1700	response	_
9-19	1701-1702	.	_

10-1	1703-1710	Methods	_
10-2	1711-1723	Twenty-eight	_
10-3	1724-1732	subjects	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-4	1733-1737	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-5	1738-1751	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-6	1752-1754	or	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-7	1755-1770	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
10-8	1771-1779	disorder	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
10-9	1780-1781	(	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
10-10	1782-1784	SZ	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
10-11	1785-1786	)	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
10-12	1787-1791	were	_
10-13	1792-1801	recruited	_
10-14	1802-1805	for	_
10-15	1806-1810	this	_
10-16	1811-1816	study	_
10-17	1817-1821	from	_
10-18	1822-1825	the	_
10-19	1826-1836	psychiatry	_
10-20	1837-1844	clinics	_
10-21	1845-1848	and	_
10-22	1849-1858	emergency	_
10-23	1859-1863	room	_
10-24	1864-1866	at	_
10-25	1867-1870	the	_
10-26	1871-1881	University	_
10-27	1882-1884	of	_
10-28	1885-1892	Alabama	_
10-29	1893-1895	at	_
10-30	1896-1906	Birmingham	_
10-31	1907-1908	(	_
10-32	1909-1912	UAB	_
10-33	1913-1914	)	_
10-34	1915-1920	based	_
10-35	1921-1923	on	_
10-36	1924-1929	being	_
10-37	1930-1933	off	_
10-38	1934-1947	antipsychotic	_
10-39	1948-1958	medication	_
10-40	1959-1962	for	_
10-41	1963-1965	at	_
10-42	1966-1971	least	_
10-43	1972-1974	10	_
10-44	1975-1979	days	_
10-45	1980-1981	.	_

11-1	1982-1993	Twenty-five	_
11-2	1994-2001	healthy	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
11-3	2002-2010	controls	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
11-4	2011-2012	(	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
11-5	2013-2015	HC	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
11-6	2016-2017	)	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
11-7	2018-2019	,	_
11-8	2020-2027	matched	_
11-9	2028-2030	on	_
11-10	2031-2034	age	_
11-11	2035-2036	,	_
11-12	2037-2040	sex	_
11-13	2041-2042	,	_
11-14	2043-2050	smoking	_
11-15	2051-2052	,	_
11-16	2053-2056	and	_
11-17	2057-2065	parental	_
11-18	2066-2076	occupation	_
11-19	2077-2078	,	_
11-20	2079-2086	without	_
11-21	2087-2095	personal	_
11-22	2096-2098	or	_
11-23	2099-2105	family	_
11-24	2106-2113	history	_
11-25	2114-2116	in	_
11-26	2117-2118	a	_
11-27	2119-2131	first-degree	_
11-28	2132-2140	relative	_
11-29	2141-2143	of	_
11-30	2144-2155	psychiatric	_
11-31	2156-2165	disorders	_
11-32	2166-2170	were	_
11-33	2171-2180	recruited	_
11-34	2181-2186	using	_
11-35	2187-2201	advertisements	_
11-36	2202-2203	.	_

12-1	2204-2213	Exclusion	_
12-2	2214-2222	criteria	_
12-3	2223-2227	were	_
12-4	2228-2233	major	_
12-5	2234-2241	medical	_
12-6	2242-2244	or	_
12-7	2245-2257	neurological	_
12-8	2258-2268	conditions	_
12-9	2269-2270	,	_
12-10	2271-2280	substance	_
12-11	2281-2284	use	_
12-12	2285-2294	disorders	_
12-13	2295-2296	(	_
12-14	2297-2303	except	_
12-15	2304-2307	for	_
12-16	2308-2316	nicotine	_
12-17	2317-2318	)	_
12-18	2319-2325	within	_
12-19	2326-2329	six	_
12-20	2330-2336	months	_
12-21	2337-2339	of	_
12-22	2340-2347	imaging	_
12-23	2348-2349	(	_
12-24	2350-2354	drug	_
12-25	2355-2361	screen	_
12-26	2362-2365	was	_
12-27	2366-2370	done	_
12-28	2371-2376	prior	_
12-29	2377-2379	to	_
12-30	2380-2388	scanning	_
12-31	2389-2390	)	_
12-32	2391-2392	,	_
12-33	2393-2397	head	_
12-34	2398-2404	injury	_
12-35	2405-2409	with	_
12-36	2410-2414	loss	_
12-37	2415-2417	of	_
12-38	2418-2431	consciousness	_
12-39	2432-2433	>	_
12-40	2434-2435	2	_
12-41	2436-2443	minutes	_
12-42	2444-2445	,	_
12-43	2446-2449	and	_
12-44	2450-2459	pregnancy	_
12-45	2460-2461	.	_

13-1	2462-2470	Subjects	_
13-2	2471-2475	gave	_
13-3	2476-2483	written	_
13-4	2484-2492	informed	_
13-5	2493-2500	consent	_
13-6	2501-2506	prior	_
13-7	2507-2509	to	_
13-8	2510-2523	participating	_
13-9	2524-2526	in	_
13-10	2527-2531	this	_
13-11	2532-2535	UAB	_
13-12	2536-2549	Institutional	_
13-13	2550-2556	Review	_
13-14	2557-2562	Board	_
13-15	2563-2571	approved	_
13-16	2572-2577	study	_
13-17	2578-2579	.	_

14-1	2580-2589	Diagnoses	_
14-2	2590-2594	were	_
14-3	2595-2606	established	_
14-4	2607-2612	using	_
14-5	2613-2621	subjects	_
14-6	2622-2623	’	_
14-7	2624-2631	medical	_
14-8	2632-2639	records	_
14-9	2640-2643	and	_
14-10	2644-2647	the	_
14-11	2648-2658	Diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
14-12	2659-2668	Interview	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
14-13	2669-2672	for	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
14-14	2673-2680	Genetic	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
14-15	2681-2688	Studies	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
14-16	2689-2690	(	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
14-17	2691-2695	DIGS	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
14-18	2696-2697	)	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
14-19	2698-2699	.	_

15-1	2700-2703	The	_
15-2	2704-2714	Repeatable	http://maven.renci.org/NeuroBridge/neurobridge#DevelopmentalNeuropsychologicalAssessment
15-3	2715-2722	Battery	http://maven.renci.org/NeuroBridge/neurobridge#DevelopmentalNeuropsychologicalAssessment
15-4	2723-2726	for	http://maven.renci.org/NeuroBridge/neurobridge#DevelopmentalNeuropsychologicalAssessment
15-5	2727-2730	the	http://maven.renci.org/NeuroBridge/neurobridge#DevelopmentalNeuropsychologicalAssessment
15-6	2731-2741	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#DevelopmentalNeuropsychologicalAssessment
15-7	2742-2744	of	http://maven.renci.org/NeuroBridge/neurobridge#DevelopmentalNeuropsychologicalAssessment
15-8	2745-2763	Neuropsychological	http://maven.renci.org/NeuroBridge/neurobridge#DevelopmentalNeuropsychologicalAssessment
15-9	2764-2770	Status	http://maven.renci.org/NeuroBridge/neurobridge#DevelopmentalNeuropsychologicalAssessment
15-10	2771-2772	(	http://maven.renci.org/NeuroBridge/neurobridge#DevelopmentalNeuropsychologicalAssessment
15-11	2773-2778	RBANS	http://maven.renci.org/NeuroBridge/neurobridge#DevelopmentalNeuropsychologicalAssessment
15-12	2779-2780	)	http://maven.renci.org/NeuroBridge/neurobridge#DevelopmentalNeuropsychologicalAssessment
15-13	2781-2794	characterized	_
15-14	2795-2802	general	_
15-15	2803-2812	cognitive	_
15-16	2813-2821	function	_
15-17	2822-2823	.	_

16-1	2824-2826	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
16-2	2827-2831	were	_
16-3	2832-2839	scanned	_
16-4	2840-2845	while	_
16-5	2846-2857	unmedicated	_
16-6	2858-2861	and	_
16-7	2862-2867	after	_
16-8	2868-2869	a	_
16-9	2870-2878	six-week	_
16-10	2879-2884	trial	_
16-11	2885-2889	with	_
16-12	2890-2901	risperidone	_
16-13	2902-2903	.	_

17-1	2904-2914	Medication	_
17-2	2915-2918	was	_
17-3	2919-2926	managed	_
17-4	2927-2929	by	_
17-5	2930-2933	two	_
17-6	2934-2947	psychiatrists	_
17-7	2948-2949	(	_
17-8	2950-2953	ACL	_
17-9	2954-2957	and	_
17-10	2958-2961	NVK	_
17-11	2962-2963	)	_
17-12	2964-2965	,	_
17-13	2966-2969	and	_
17-14	2970-2974	dose	_
17-15	2975-2989	determinations	_
17-16	2990-2994	were	_
17-17	2995-3000	based	_
17-18	3001-3003	on	_
17-19	3004-3015	therapeutic	_
17-20	3016-3019	and	_
17-21	3020-3024	side	_
17-22	3025-3032	effects	_
17-23	3033-3034	.	_

18-1	3035-3043	Starting	_
18-2	3044-3049	doses	_
18-3	3050-3054	were	_
18-4	3055-3060	1–3mg	_
18-5	3061-3062	;	_
18-6	3063-3072	titration	_
18-7	3073-3076	was	_
18-8	3077-3081	done	_
18-9	3082-3084	in	_
18-10	3085-3090	1–2mg	_
18-11	3091-3101	increments	_
18-12	3102-3103	.	_

19-1	3104-3107	Use	_
19-2	3108-3110	of	_
19-3	3111-3122	concomitant	_
19-4	3123-3134	medications	_
19-5	3135-3138	was	_
19-6	3139-3148	permitted	_
19-7	3149-3151	as	_
19-8	3152-3162	clinically	_
19-9	3163-3172	indicated	_
19-10	3173-3174	.	_

20-1	3175-3182	Symptom	_
20-2	3183-3191	severity	_
20-3	3192-3195	was	_
20-4	3196-3204	assessed	_
20-5	3205-3211	weekly	_
20-6	3212-3217	using	_
20-7	3218-3221	the	_
20-8	3222-3227	Brief	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
20-9	3228-3239	Psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
20-10	3240-3246	Rating	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
20-11	3247-3252	Scale	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
20-12	3253-3254	(	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
20-13	3255-3259	BPRS	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
20-14	3260-3261	)	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
20-15	3262-3263	.	_

21-1	3264-3274	Medication	_
21-2	3275-3285	compliance	_
21-3	3286-3289	was	_
21-4	3290-3299	monitored	_
21-5	3300-3302	by	_
21-6	3303-3309	weekly	_
21-7	3310-3314	pill	_
21-8	3315-3320	count	_
21-9	3321-3322	.	_

22-1	3323-3325	HC	_
22-2	3326-3330	were	_
22-3	3331-3338	scanned	_
22-4	3339-3344	twice	_
22-5	3345-3348	six	_
22-6	3349-3354	weeks	_
22-7	3355-3360	apart	_
22-8	3361-3362	.	_

23-1	3363-3371	Subjects	_
23-2	3372-3376	were	_
23-3	3377-3385	excluded	_
23-4	3386-3389	due	_
23-5	3390-3392	to	_
23-6	3393-3399	excess	_
23-7	3400-3408	movement	_
23-8	3409-3410	(	_
23-9	3411-3412	>	_
23-10	3413-3416	2mm	_
23-11	3417-3428	translation	_
23-12	3429-3430	;	_
23-13	3431-3433	2°	_
23-14	3434-3442	rotation	_
23-15	3443-3449	within	_
23-16	3450-3451	a	_
23-17	3452-3455	run	_
23-18	3456-3457	;	_
23-19	3458-3459	4	_
23-20	3460-3462	SZ	_
23-21	3463-3464	,	_
23-22	3465-3466	2	_
23-23	3467-3469	HC	_
23-24	3470-3471	)	_
23-25	3472-3474	or	_
23-26	3475-3479	lack	_
23-27	3480-3482	of	_
23-28	3483-3491	complete	_
23-29	3492-3496	task	_
23-30	3497-3508	performance	_
23-31	3509-3510	,	_
23-32	3511-3518	defined	_
23-33	3519-3521	as	_
23-34	3522-3524	no	_
23-35	3525-3534	responses	_
23-36	3535-3537	to	_
23-37	3538-3542	more	_
23-38	3543-3547	than	_
23-39	3548-3549	¼	_
23-40	3550-3552	of	_
23-41	3553-3556	the	_
23-42	3557-3562	total	_
23-43	3563-3569	number	_
23-44	3570-3572	of	_
23-45	3573-3579	trials	_
23-46	3580-3581	,	_
23-47	3582-3583	(	_
23-48	3584-3585	2	_
23-49	3586-3588	SZ	_
23-50	3589-3597	baseline	_
23-51	3598-3599	,	_
23-52	3600-3601	2	_
23-53	3602-3604	SZ	_
23-54	3605-3609	week	_
23-55	3610-3613	six	_
23-56	3614-3615	,	_
23-57	3616-3617	3	_
23-58	3618-3620	HC	_
23-59	3621-3622	)	_
23-60	3623-3624	,	_
23-61	3625-3632	leaving	_
23-62	3633-3635	22	_
23-63	3636-3638	SZ	_
23-64	3639-3642	and	_
23-65	3643-3645	20	_
23-66	3646-3648	HC	_
23-67	3649-3651	at	_
23-68	3652-3660	baseline	_
23-69	3661-3664	and	_
23-70	3665-3667	20	_
23-71	3668-3670	SZ	_
23-72	3671-3674	and	_
23-73	3675-3677	20	_
23-74	3678-3680	HC	_
23-75	3681-3683	at	_
23-76	3684-3688	week	_
23-77	3689-3692	six	_
23-78	3693-3694	.	_

24-1	3695-3699	Task	_
24-2	3700-3708	Subjects	_
24-3	3709-3718	performed	_
24-4	3719-3720	a	_
24-5	3721-3733	computerized	_
24-6	3734-3741	version	_
24-7	3742-3744	of	_
24-8	3745-3748	the	_
24-9	3749-3755	Stroop	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
24-10	3756-3768	color-naming	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
24-11	3769-3773	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
24-12	3774-3775	.	_

25-1	3776-3783	Stimuli	_
25-2	3784-3793	consisted	_
25-3	3794-3796	of	_
25-4	3797-3802	three	_
25-5	3803-3808	words	_
25-6	3809-3810	:	_
25-7	3811-3812	“	_
25-8	3813-3816	RED	_
25-9	3817-3818	”	_
25-10	3819-3820	,	_
25-11	3821-3822	“	_
25-12	3823-3828	GREEN	_
25-13	3829-3830	”	_
25-14	3831-3832	,	_
25-15	3833-3835	or	_
25-16	3836-3837	“	_
25-17	3838-3842	BLUE	_
25-18	3843-3844	,	_
25-19	3845-3846	”	_
25-20	3847-3856	displayed	_
25-21	3857-3859	in	_
25-22	3860-3863	one	_
25-23	3864-3866	of	_
25-24	3867-3870	the	_
25-25	3871-3884	corresponding	_
25-26	3885-3891	colors	_
25-27	3892-3893	.	_

26-1	3894-3900	Trials	_
26-2	3901-3905	were	_
26-3	3906-3912	either	_
26-4	3913-3914	“	_
26-5	3915-3924	congruent	_
26-6	3925-3926	”	_
26-7	3927-3929	or	_
26-8	3930-3931	“	_
26-9	3932-3943	incongruent	_
26-10	3944-3945	,	_
26-11	3946-3947	”	_
26-12	3948-3953	where	_
26-13	3954-3957	the	_
26-14	3958-3962	word	_
26-15	3963-3966	and	_
26-16	3967-3970	the	_
26-17	3971-3976	color	_
26-18	3977-3979	of	_
26-19	3980-3983	the	_
26-20	3984-3988	word	_
26-21	3989-3997	differed	_
26-22	3998-4000	in	_
26-23	4001-4012	incongruent	_
26-24	4013-4019	trials	_
26-25	4020-4021	.	_

27-1	4022-4030	Subjects	_
27-2	4031-4035	were	_
27-3	4036-4046	instructed	_
27-4	4047-4049	to	_
27-5	4050-4058	indicate	_
27-6	4059-4062	the	_
27-7	4063-4068	color	_
27-8	4069-4072	but	_
27-9	4073-4079	ignore	_
27-10	4080-4083	the	_
27-11	4084-4088	word	_
27-12	4089-4092	and	_
27-13	4093-4095	to	_
27-14	4096-4103	respond	_
27-15	4104-4106	as	_
27-16	4107-4114	quickly	_
27-17	4115-4118	and	_
27-18	4119-4121	as	_
27-19	4122-4132	accurately	_
27-20	4133-4135	as	_
27-21	4136-4144	possible	_
27-22	4145-4146	.	_

28-1	4147-4156	Responses	_
28-2	4157-4161	were	_
28-3	4162-4170	recorded	_
28-4	4171-4173	by	_
28-5	4174-4180	button	_
28-6	4181-4186	press	_
28-7	4187-4192	using	_
28-8	4193-4195	an	_
28-9	4196-4203	IFIS-SA	_
28-10	4204-4210	system	_
28-11	4211-4212	(	_
28-12	4213-4215	In	_
28-13	4216-4220	Vivo	_
28-14	4221-4222	,	_
28-15	4223-4230	Orlando	_
28-16	4231-4232	,	_
28-17	4233-4240	Florida	_
28-18	4241-4242	)	_
28-19	4243-4250	running	_
28-20	4251-4258	E-Prime	_
28-21	4259-4260	(	_
28-22	4261-4268	version	_
28-23	4269-4272	1.2	_
28-24	4273-4274	;	_
28-25	4275-4285	Psychology	_
28-26	4286-4294	Software	_
28-27	4295-4300	Tools	_
28-28	4301-4302	,	_
28-29	4303-4313	Pittsburgh	_
28-30	4314-4315	,	_
28-31	4316-4328	Pennsylvania	_
28-32	4329-4330	)	_
28-33	4331-4332	.	_

29-1	4333-4336	The	_
29-2	4337-4350	event-related	_
29-3	4351-4357	design	http://maven.renci.org/NeuroBridge/neurobridge#StudyDesign
29-4	4358-4367	consisted	http://maven.renci.org/NeuroBridge/neurobridge#StudyDesign
29-5	4368-4370	of	http://maven.renci.org/NeuroBridge/neurobridge#StudyDesign
29-6	4371-4376	three	_
29-7	4377-4381	runs	_
29-8	4382-4384	of	_
29-9	4385-4387	88	_
29-10	4388-4394	trials	_
29-11	4395-4398	per	_
29-12	4399-4402	run	_
29-13	4403-4404	(	_
29-14	4405-4408	~30	_
29-15	4409-4410	%	_
29-16	4411-4422	incongruent	_
29-17	4423-4424	,	_
29-18	4425-4427	70	_
29-19	4428-4429	%	_
29-20	4430-4439	congruent	_
29-21	4440-4441	)	_
29-22	4442-4443	.	_

30-1	4444-4447	The	_
30-2	4448-4449	3	_
30-3	4450-4457	seconds	_
30-4	4458-4464	trials	_
30-5	4465-4469	were	_
30-6	4470-4479	comprised	_
30-7	4480-4482	of	_
30-8	4483-4484	a	_
30-9	4485-4489	word	_
30-10	4490-4498	stimulus	_
30-11	4499-4502	for	_
30-12	4503-4506	1.5	_
30-13	4507-4514	seconds	_
30-14	4515-4518	and	_
30-15	4519-4520	a	_
30-16	4521-4529	fixation	_
30-17	4530-4535	cross	_
30-18	4536-4539	for	_
30-19	4540-4543	1.5	_
30-20	4544-4551	seconds	_
30-21	4552-4553	.	_

31-1	4554-4562	Subjects	_
31-2	4563-4572	completed	_
31-3	4573-4574	a	_
31-4	4575-4583	practice	_
31-5	4584-4587	run	_
31-6	4588-4594	before	_
31-7	4595-4599	each	_
31-8	4600-4608	scanning	_
31-9	4609-4616	session	_
31-10	4617-4618	.	_

32-1	4619-4624	Image	_
32-2	4625-4636	Acquisition	_
32-3	4637-4644	Imaging	_
32-4	4645-4648	was	_
32-5	4649-4658	performed	_
32-6	4659-4661	on	_
32-7	4662-4663	a	_
32-8	4664-4666	3T	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
32-9	4667-4676	head-only	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
32-10	4677-4680	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
32-11	4681-4688	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
32-12	4689-4690	(	_
32-13	4691-4699	Magnetom	_
32-14	4700-4707	Allegra	_
32-15	4708-4709	,	_
32-16	4710-4717	Siemens	_
32-17	4718-4725	Medical	_
32-18	4726-4735	Solutions	_
32-19	4736-4737	,	_
32-20	4738-4746	Erlangen	_
32-21	4747-4748	,	_
32-22	4749-4756	Germany	_
32-23	4757-4758	)	_
32-24	4759-4760	,	_
32-25	4761-4765	with	_
32-26	4766-4767	a	_
32-27	4768-4778	circularly	_
32-28	4779-4788	polarized	_
32-29	4789-4805	transmit/receive	_
32-30	4806-4810	head	_
32-31	4811-4815	coil	_
32-32	4816-4817	.	_

33-1	4818-4822	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
33-2	4823-4827	data	_
33-3	4828-4832	were	_
33-4	4833-4841	acquired	_
33-5	4842-4847	using	_
33-6	4848-4851	the	_
33-7	4852-4860	gradient	_
33-8	4861-4869	recalled	_
33-9	4870-4881	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
33-10	4882-4889	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
33-11	4890-4898	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
33-12	4899-4900	(	_
33-13	4901-4911	repetition	_
33-14	4912-4921	time/echo	_
33-15	4922-4926	time	_
33-16	4927-4928	[	_
33-17	4929-4934	TR/TE	_
33-18	4935-4936	]	_
33-19	4937-4938	=	_
33-20	4939-4946	2100/30	_
33-21	4947-4959	milliseconds	_
33-22	4960-4961	,	_
33-23	4962-4966	flip	_
33-24	4967-4973	angle=	_
33-25	4974-4977	70°	_
33-26	4978-4979	,	_
33-27	4980-4985	field	_
33-28	4986-4988	of	_
33-29	4989-4994	view=	_
33-30	4995-4998	24×	_
33-31	4999-5004	24cm2	_
33-32	5005-5006	,	_
33-33	5007-5009	64	_
33-34	5010-5011	×	_
33-35	5012-5014	64	_
33-36	5015-5021	matrix	_
33-37	5022-5023	,	_
33-38	5024-5027	4mm	_
33-39	5028-5033	slice	_
33-40	5034-5043	thickness	_
33-41	5044-5045	,	_
33-42	5046-5049	1mm	_
33-43	5050-5053	gap	_
33-44	5054-5055	,	_
33-45	5056-5058	26	_
33-46	5059-5064	axial	_
33-47	5065-5071	slices	_
33-48	5072-5073	)	_
33-49	5074-5075	.	_

34-1	5076-5077	A	_
34-2	5078-5093	high-resolution	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
34-3	5094-5104	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
34-4	5105-5109	scan	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
34-5	5110-5113	was	_
34-6	5114-5122	acquired	_
34-7	5123-5126	for	_
34-8	5127-5137	anatomical	_
34-9	5138-5147	reference	_
34-10	5148-5149	(	_
34-11	5150-5156	MPRAGE	_
34-12	5157-5158	;	_
34-13	5159-5174	TR/TE/inversion	_
34-14	5175-5179	time	_
34-15	5180-5181	[	_
34-16	5182-5184	TI	_
34-17	5185-5186	]	_
34-18	5187-5188	=	_
34-19	5189-5203	2300/3.93/1100	_
34-20	5204-5216	milliseconds	_
34-21	5217-5218	,	_
34-22	5219-5223	flip	_
34-23	5224-5230	angle=	_
34-24	5231-5234	12°	_
34-25	5235-5236	,	_
34-26	5237-5240	256	_
34-27	5241-5242	×	_
34-28	5243-5246	256	_
34-29	5247-5253	matrix	_
34-30	5254-5255	,	_
34-31	5256-5260	1mm3	_
34-32	5261-5266	voxel	_
34-33	5267-5271	size	_
34-34	5272-5273	)	_
34-35	5274-5275	.	_

35-1	5276-5284	Analyses	_
35-2	5285-5292	between	_
35-3	5293-5299	groups	_
35-4	5300-5303	and	_
35-5	5304-5310	across	_
35-6	5311-5315	time	_
35-7	5316-5321	found	_
35-8	5322-5324	no	_
35-9	5325-5336	significant	_
35-10	5337-5348	differences	_
35-11	5349-5351	in	_
35-12	5352-5356	mean	_
35-13	5357-5369	scan-to-scan	_
35-14	5370-5374	head	_
35-15	5375-5383	movement	_
35-16	5384-5387	for	_
35-17	5388-5391	the	_
35-18	5392-5395	six	_
35-19	5396-5404	movement	_
35-20	5405-5415	parameters	_
35-21	5416-5417	.	_

36-1	5418-5429	Statistical	_
36-2	5430-5438	Analysis	_
36-3	5439-5447	Analyses	_
36-4	5448-5452	were	_
36-5	5453-5462	conducted	_
36-6	5463-5465	in	_
36-7	5466-5470	SPSS	_
36-8	5471-5473	20	_
36-9	5474-5475	(	_
36-10	5476-5479	IBM	_
36-11	5480-5484	SPSS	_
36-12	5485-5489	Inc.	_
36-13	5490-5491	,	_
36-14	5492-5499	Chicago	_
36-15	5500-5501	,	_
36-16	5502-5504	IL	_
36-17	5505-5506	)	_
36-18	5507-5508	.	_

37-1	5509-5514	Group	_
37-2	5515-5526	comparisons	_
37-3	5527-5531	were	_
37-4	5532-5541	performed	_
37-5	5542-5547	using	_
37-6	5548-5558	chi-square	_
37-7	5559-5561	or	_
37-8	5562-5570	analysis	_
37-9	5571-5573	of	_
37-10	5574-5582	variance	_
37-11	5583-5584	,	_
37-12	5585-5587	as	_
37-13	5588-5599	appropriate	_
37-14	5600-5601	.	_

38-1	5602-5610	Analyzes	_
38-2	5611-5613	of	_
38-3	5614-5622	reaction	_
38-4	5623-5627	time	_
38-5	5628-5629	(	_
38-6	5630-5632	RT	_
38-7	5633-5634	)	_
38-8	5635-5638	for	_
38-9	5639-5646	correct	_
38-10	5647-5653	trials	_
38-11	5654-5655	[	_
38-12	5656-5665	congruent	_
38-13	5666-5667	,	_
38-14	5668-5679	incongruent	_
38-15	5680-5681	,	_
38-16	5682-5685	and	_
38-17	5686-5692	Stroop	_
38-18	5693-5694	(	_
38-19	5695-5706	incongruent	_
38-20	5707-5708	-	_
38-21	5709-5718	congruent	_
38-22	5719-5720	)	_
38-23	5721-5722	]	_
38-24	5723-5726	and	_
38-25	5727-5733	errors	_
38-26	5734-5735	(	_
38-27	5736-5745	congruent	_
38-28	5746-5747	,	_
38-29	5748-5759	incongruent	_
38-30	5760-5761	)	_
38-31	5762-5766	were	_
38-32	5767-5775	analyzed	_
38-33	5776-5781	using	_
38-34	5782-5788	linear	_
38-35	5789-5794	mixed	_
38-36	5795-5801	models	_
38-37	5802-5811	comparing	_
38-38	5812-5817	fixed	_
38-39	5818-5825	effects	_
38-40	5826-5828	of	_
38-41	5829-5834	group	_
38-42	5835-5836	(	_
38-43	5837-5839	HC	_
38-44	5840-5842	vs	_
38-45	5843-5845	SZ	_
38-46	5846-5847	)	_
38-47	5848-5849	,	_
38-48	5850-5854	time	_
38-49	5855-5856	(	_
38-50	5857-5868	unmedicated	_
38-51	5869-5871	vs	_
38-52	5872-5876	week	_
38-53	5877-5880	six	_
38-54	5881-5882	)	_
38-55	5883-5884	,	_
38-56	5885-5894	condition	_
38-57	5895-5896	(	_
38-58	5897-5906	congruent	_
38-59	5907-5909	vs	_
38-60	5910-5921	incongruent	_
38-61	5922-5923	)	_
38-62	5924-5925	,	_
38-63	5926-5929	and	_
38-64	5930-5942	interactions	_
38-65	5943-5944	.	_

39-1	5945-5949	Post	_
39-2	5950-5953	hoc	_
39-3	5954-5962	analyses	_
39-4	5963-5967	were	_
39-5	5968-5977	performed	_
39-6	5978-5983	where	_
39-7	5984-5995	appropriate	_
39-8	5996-6000	with	_
39-9	6001-6011	Bonferroni	_
39-10	6012-6023	corrections	_
39-11	6024-6025	.	_

40-1	6026-6031	Image	_
40-2	6032-6040	analyses	_
40-3	6041-6045	Data	_
40-4	6046-6054	analyses	_
40-5	6055-6059	were	_
40-6	6060-6071	implemented	_
40-7	6072-6074	in	_
40-8	6075-6079	SPM8	_
40-9	6080-6081	(	_
40-10	6082-6090	Wellcome	_
40-11	6091-6096	Trust	_
40-12	6097-6103	Centre	_
40-13	6104-6107	for	_
40-14	6108-6120	Neuroimaging	_
40-15	6121-6122	)	_
40-16	6123-6124	.	_

41-1	6125-6138	Preprocessing	_
41-2	6139-6147	included	_
41-3	6148-6160	slice-timing	_
41-4	6161-6171	correction	_
41-5	6172-6173	,	_
41-6	6174-6185	realignment	_
41-7	6186-6187	,	_
41-8	6188-6197	reslicing	_
41-9	6198-6200	at	_
41-10	6201-6206	1.5mm	_
41-11	6207-6216	isotropic	_
41-12	6217-6223	voxels	_
41-13	6224-6225	,	_
41-14	6226-6241	motion/artifact	_
41-15	6242-6252	correction	_
41-16	6253-6258	using	_
41-17	6259-6268	ArtRepair	_
41-18	6269-6270	,	_
41-19	6271-6277	DARTEL	_
41-20	6278-6291	normalization	_
41-21	6292-6293	,	_
41-22	6294-6297	and	_
41-23	6298-6307	smoothing	_
41-24	6308-6309	(	_
41-25	6310-6313	4mm	_
41-26	6314-6318	full	_
41-27	6319-6324	width	_
41-28	6325-6327	at	_
41-29	6328-6332	half	_
41-30	6333-6340	maximum	_
41-31	6341-6349	Gaussian	_
41-32	6350-6356	kernel	_
41-33	6357-6358	)	_
41-34	6359-6360	.	_

42-1	6361-6369	Analysis	_
42-2	6370-6373	for	_
42-3	6374-6377	the	_
42-4	6378-6384	Stroop	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
42-5	6385-6389	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
42-6	6390-6399	consisted	_
42-7	6400-6402	of	_
42-8	6403-6404	a	_
42-9	6405-6419	single-subject	_
42-10	6420-6434	voxel-by-voxel	_
42-11	6435-6442	general	_
42-12	6443-6449	linear	_
42-13	6450-6455	model	_
42-14	6456-6457	.	_

43-1	6458-6462	Five	_
43-2	6463-6473	conditions	_
43-3	6474-6478	were	_
43-4	6479-6487	included	_
43-5	6488-6489	:	_
43-6	6490-6501	incongruent	_
43-7	6502-6503	,	_
43-8	6504-6513	congruent	_
43-9	6514-6515	,	_
43-10	6516-6524	stimulus	_
43-11	6525-6536	repetitions	_
43-12	6537-6538	(	_
43-13	6539-6544	exact	_
43-14	6545-6555	repetition	_
43-15	6556-6558	of	_
43-16	6559-6560	a	_
43-17	6561-6569	previous	_
43-18	6570-6575	trial	_
43-19	6576-6577	)	_
43-20	6578-6579	,	_
43-21	6580-6585	error	_
43-22	6586-6587	,	_
43-23	6588-6591	and	_
43-24	6592-6594	no	_
43-25	6595-6603	response	_
43-26	6604-6610	trials	_
43-27	6611-6612	.	_

44-1	6613-6616	The	_
44-2	6617-6627	conditions	_
44-3	6628-6632	were	_
44-4	6633-6642	convolved	_
44-5	6643-6647	with	_
44-6	6648-6651	the	_
44-7	6652-6661	canonical	_
44-8	6662-6673	hemodynamic	_
44-9	6674-6682	response	_
44-10	6683-6691	function	_
44-11	6692-6696	with	_
44-12	6697-6705	temporal	_
44-13	6706-6717	derivatives	_
44-14	6718-6719	.	_

45-1	6720-6723	The	_
45-2	6724-6732	contrast	_
45-3	6733-6735	of	_
45-4	6736-6744	interest	_
45-5	6745-6748	was	_
45-6	6749-6756	correct	_
45-7	6757-6768	incongruent	_
45-8	6769-6775	trials	_
45-9	6776-6781	minus	_
45-10	6782-6789	correct	_
45-11	6790-6799	congruent	_
45-12	6800-6806	trials	_
45-13	6807-6808	,	_
45-14	6809-6821	subsequently	_
45-15	6822-6830	referred	_
45-16	6831-6833	to	_
45-17	6834-6836	as	_
45-18	6837-6840	the	_
45-19	6841-6847	Stroop	_
45-20	6848-6854	effect	_
45-21	6855-6856	.	_

46-1	6857-6858	A	_
46-2	6859-6867	contrast	_
46-3	6868-6873	z-map	_
46-4	6874-6876	of	_
46-5	6877-6880	the	_
46-6	6881-6885	BOLD	_
46-7	6886-6892	signal	_
46-8	6893-6899	during	_
46-9	6900-6903	the	_
46-10	6904-6910	Stroop	_
46-11	6911-6917	effect	_
46-12	6918-6921	was	_
46-13	6922-6931	generated	_
46-14	6932-6935	for	_
46-15	6936-6940	each	_
46-16	6941-6948	subject	_
46-17	6949-6951	at	_
46-18	6952-6956	each	_
46-19	6957-6961	time	_
46-20	6962-6967	point	_
46-21	6968-6969	.	_

47-1	6970-6981	Generalized	_
47-2	6982-7002	psycho-physiological	_
47-3	7003-7014	interaction	_
47-4	7015-7016	(	_
47-5	7017-7021	gPPI	_
47-6	7022-7023	)	_
47-7	7024-7026	is	_
47-8	7027-7029	an	_
47-9	7030-7038	analysis	_
47-10	7039-7045	method	_
47-11	7046-7050	that	_
47-12	7051-7063	investigates	_
47-13	7064-7074	functional	_
47-14	7075-7087	connectivity	_
47-15	7088-7095	between	_
47-16	7096-7097	a	_
47-17	7098-7106	selected	_
47-18	7107-7112	brain	_
47-19	7113-7119	region	_
47-20	7120-7123	and	_
47-21	7124-7127	the	_
47-22	7128-7132	rest	_
47-23	7133-7135	of	_
47-24	7136-7139	the	_
47-25	7140-7145	brain	_
47-26	7146-7152	during	_
47-27	7153-7156	the	_
47-28	7157-7165	presence	_
47-29	7166-7168	of	_
47-30	7169-7173	task	_
47-31	7174-7184	conditions	_
47-32	7185-7186	.	_

48-1	7187-7191	gPPI	_
48-2	7192-7200	analysis	_
48-3	7201-7203	is	_
48-4	7204-7206	an	_
48-5	7207-7218	interaction	_
48-6	7219-7227	analysis	_
48-7	7228-7232	that	_
48-8	7233-7239	allows	_
48-9	7240-7243	one	_
48-10	7244-7246	to	_
48-11	7247-7254	analyze	_
48-12	7255-7262	changes	_
48-13	7263-7265	in	_
48-14	7266-7278	connectivity	_
48-15	7279-7285	across	_
48-16	7286-7296	conditions	_
48-17	7297-7298	,	_
48-18	7299-7301	in	_
48-19	7302-7306	this	_
48-20	7307-7311	case	_
48-21	7312-7319	between	_
48-22	7320-7323	the	_
48-23	7324-7335	incongruent	_
48-24	7336-7339	and	_
48-25	7340-7349	congruent	_
48-26	7350-7360	conditions	_
48-27	7361-7362	,	_
48-28	7363-7366	and	_
48-29	7367-7373	allows	_
48-30	7374-7378	more	_
48-31	7379-7390	flexibility	_
48-32	7391-7393	in	_
48-33	7394-7402	analyses	_
48-34	7403-7411	compared	_
48-35	7412-7414	to	_
48-36	7415-7423	standard	_
48-37	7424-7427	PPI	_
48-38	7428-7429	.	_

49-1	7430-7436	Stroop	_
49-2	7437-7453	effect-dependent	_
49-3	7454-7466	connectivity	_
49-4	7467-7471	with	_
49-5	7472-7475	the	_
49-6	7476-7479	ACC	_
49-7	7480-7481	(	_
49-8	7482-7489	defined	_
49-9	7490-7495	using	_
49-10	7496-7499	the	_
49-11	7500-7506	IBASPM	_
49-12	7507-7510	116	_
49-13	7511-7514	WFU	_
49-14	7515-7524	pickatlas	_
49-15	7525-7529	with	_
49-16	7530-7540	subsequent	_
49-17	7541-7552	restriction	_
49-18	7553-7555	of	_
49-19	7556-7561	being	_
49-20	7562-7565	one	_
49-21	7566-7571	slice	_
49-22	7572-7579	forward	_
49-23	7580-7584	from	_
49-24	7585-7588	the	_
49-25	7589-7602	disappearance	_
49-26	7603-7605	of	_
49-27	7606-7609	the	_
49-28	7610-7618	juncture	_
49-29	7619-7621	of	_
49-30	7622-7625	the	_
49-31	7626-7634	anterior	_
49-32	7635-7641	corpus	_
49-33	7642-7650	callosum	_
49-34	7651-7655	from	_
49-35	7656-7660	both	_
49-36	7661-7672	hemispheres	_
49-37	7673-7676	and	_
49-38	7677-7680	the	_
49-39	7681-7690	posterior	_
49-40	7691-7694	end	_
49-41	7695-7697	as	_
49-42	7698-7701	the	_
49-43	7702-7707	first	_
49-44	7708-7716	vertical	_
49-45	7717-7722	slice	_
49-46	7723-7732	posterior	_
49-47	7733-7735	to	_
49-48	7736-7739	the	_
49-49	7740-7748	anterior	_
49-50	7749-7759	commissure	_
49-51	7760-7761	)	_
49-52	7762-7765	was	_
49-53	7766-7774	assessed	_
49-54	7775-7780	using	_
49-55	7781-7784	the	_
49-56	7785-7789	gPPI	_
49-57	7790-7797	toolbox	_
49-58	7798-7799	.	_

50-1	7800-7802	On	_
50-2	7803-7814	first-level	_
50-3	7815-7816	,	_
50-4	7817-7820	the	_
50-5	7821-7825	gPPI	_
50-6	7826-7834	analysis	_
50-7	7835-7843	included	_
50-8	7844-7847	the	_
50-9	7848-7857	following	_
50-10	7858-7868	regressors	_
50-11	7869-7870	:	_
50-12	7871-7874	the	_
50-13	7875-7888	psychological	_
50-14	7889-7898	component	_
50-15	7899-7901	of	_
50-16	7902-7905	the	_
50-17	7906-7910	task	_
50-18	7911-7920	condition	_
50-19	7921-7922	(	_
50-20	7923-7932	congruent	_
50-21	7933-7934	,	_
50-22	7935-7946	incongruent	_
50-23	7947-7948	)	_
50-24	7949-7950	,	_
50-25	7951-7954	the	_
50-26	7955-7968	physiological	_
50-27	7969-7978	component	_
50-28	7979-7980	(	_
50-29	7981-7985	time	_
50-30	7986-7992	course	_
50-31	7993-7995	of	_
50-32	7996-8006	activation	_
50-33	8007-8009	in	_
50-34	8010-8013	the	_
50-35	8014-8017	ACC	_
50-36	8018-8024	region	_
50-37	8025-8026	)	_
50-38	8027-8030	and	_
50-39	8031-8034	the	_
50-40	8035-8054	psychophysiological	_
50-41	8055-8066	interaction	_
50-42	8067-8069	of	_
50-43	8070-8075	these	_
50-44	8076-8079	two	_
50-45	8080-8090	components	_
50-46	8091-8101	throughout	_
50-47	8102-8105	the	_
50-48	8106-8111	whole	_
50-49	8112-8117	brain	_
50-50	8118-8119	.	_

51-1	8120-8123	The	_
51-2	8124-8130	Stroop	_
51-3	8131-8137	effect	_
51-4	8138-8146	contrast	_
51-5	8147-8156	condition	_
51-6	8157-8160	was	_
51-7	8161-8168	created	_
51-8	8169-8171	by	_
51-9	8172-8183	subtracting	_
51-10	8184-8187	the	_
51-11	8188-8192	gPPI	_
51-12	8193-8204	interaction	_
51-13	8205-8214	regressor	_
51-14	8215-8217	of	_
51-15	8218-8221	the	_
51-16	8222-8231	congruent	_
51-17	8232-8241	condition	_
51-18	8242-8246	from	_
51-19	8247-8250	the	_
51-20	8251-8262	interaction	_
51-21	8263-8272	regressor	_
51-22	8273-8275	of	_
51-23	8276-8279	the	_
51-24	8280-8291	incongruent	_
51-25	8292-8301	condition	_
51-26	8302-8303	.	_

52-1	8304-8305	A	_
52-2	8306-8314	contrast	_
52-3	8315-8318	map	_
52-4	8319-8321	of	_
52-5	8322-8325	the	_
52-6	8326-8337	interaction	_
52-7	8338-8340	of	_
52-8	8341-8349	interest	_
52-9	8350-8351	,	_
52-10	8352-8358	Stroop	_
52-11	8359-8365	effect	_
52-12	8366-8367	×	_
52-13	8368-8371	ACC	_
52-14	8372-8382	activation	_
52-15	8383-8394	interaction	_
52-16	8395-8396	,	_
52-17	8397-8400	was	_
52-18	8401-8410	generated	_
52-19	8411-8414	for	_
52-20	8415-8419	each	_
52-21	8420-8427	subject	_
52-22	8428-8430	at	_
52-23	8431-8435	each	_
52-24	8436-8440	time	_
52-25	8441-8446	point	_
52-26	8447-8448	.	_

53-1	8449-8451	On	_
53-2	8452-8464	second-level	_
53-3	8465-8466	,	_
53-4	8467-8475	between-	_
53-5	8476-8481	group	_
53-6	8482-8493	differences	_
53-7	8494-8497	for	_
53-8	8498-8506	baseline	_
53-9	8507-8517	ACC-Stroop	_
53-10	8518-8524	effect	_
53-11	8525-8535	functional	_
53-12	8536-8548	connectivity	_
53-13	8549-8553	were	_
53-14	8554-8567	characterized	_
53-15	8568-8571	via	_
53-16	8572-8573	a	_
53-17	8574-8584	two-sample	_
53-18	8585-8591	t-test	_
53-19	8592-8598	within	_
53-20	8599-8602	SPM	_
53-21	8603-8604	.	_

54-1	8605-8616	Exploratory	_
54-2	8617-8625	analyses	_
54-3	8626-8627	:	_
54-4	8628-8630	in	_
54-5	8631-8638	regions	_
54-6	8639-8644	where	_
54-7	8645-8653	baseline	_
54-8	8654-8664	functional	_
54-9	8665-8677	connectivity	_
54-10	8678-8681	was	_
54-11	8682-8695	significantly	_
54-12	8696-8705	different	_
54-13	8706-8713	between	_
54-14	8714-8720	groups	_
54-15	8721-8722	,	_
54-16	8723-8726	the	_
54-17	8727-8732	first	_
54-18	8733-8745	eigenvariate	_
54-19	8746-8748	of	_
54-20	8749-8759	functional	_
54-21	8760-8772	connectivity	_
54-22	8773-8776	was	_
54-23	8777-8786	extracted	_
54-24	8787-8790	for	_
54-25	8791-8795	each	_
54-26	8796-8806	individual	_
54-27	8807-8810	via	_
54-28	8811-8814	REX	_
54-29	8815-8816	(	_
54-30	8817-8822	CIBSR	_
54-31	8823-8831	Stanford	_
54-32	8832-8842	University	_
54-33	8843-8844	,	_
54-34	8845-8847	CA	_
54-35	8848-8849	)	_
54-36	8850-8855	using	_
54-37	8856-8857	a	_
54-38	8858-8861	6mm	_
54-39	8862-8868	sphere	_
54-40	8869-8877	centered	_
54-41	8878-8880	on	_
54-42	8881-8884	the	_
54-43	8885-8892	maximum	_
54-44	8893-8902	intensity	_
54-45	8903-8914	projections	_
54-46	8915-8916	;	_
54-47	8917-8922	these	_
54-48	8923-8929	values	_
54-49	8930-8934	were	_
54-50	8935-8942	plotted	_
54-51	8943-8950	against	_
54-52	8951-8958	average	_
54-53	8959-8965	errors	_
54-54	8966-8969	and	_
54-55	8970-8976	Stroop	_
54-56	8977-8979	RT	_
54-57	8980-8983	and	_
54-58	8984-8986	R2	_
54-59	8987-8993	values	_
54-60	8994-8995	(	_
54-61	8996-9005	converted	_
54-62	9006-9008	to	_
54-63	9009-9010	z	_
54-64	9011-9012	)	_
54-65	9013-9021	compared	_
54-66	9022-9029	between	_
54-67	9030-9036	groups	_
54-68	9037-9038	.	_

55-1	9039-9046	Outlier	_
55-2	9047-9053	values	_
55-3	9054-9060	beyond	_
55-4	9061-9064	two	_
55-5	9065-9073	standard	_
55-6	9074-9084	deviations	_
55-7	9085-9089	were	_
55-8	9090-9097	removed	_
55-9	9098-9102	from	_
55-10	9103-9106	the	_
55-11	9107-9118	descriptive	_
55-12	9119-9124	plots	_
55-13	9125-9128	and	_
55-14	9129-9140	correlation	_
55-15	9141-9149	analysis	_
55-16	9150-9157	between	_
55-17	9158-9170	connectivity	_
55-18	9171-9177	values	_
55-19	9178-9181	and	_
55-20	9182-9188	Stroop	_
55-21	9189-9200	performance	_
55-22	9201-9202	(	_
55-23	9203-9205	RT	_
55-24	9206-9209	and	_
55-25	9210-9216	errors	_
55-26	9217-9218	)	_
55-27	9219-9225	values	_
55-28	9226-9227	.	_

56-1	9228-9230	To	_
56-2	9231-9238	examine	_
56-3	9239-9242	APD	_
56-4	9243-9250	effects	_
56-5	9251-9253	on	_
56-6	9254-9264	functional	_
56-7	9265-9277	connectivity	_
56-8	9278-9279	,	_
56-9	9280-9282	we	_
56-10	9283-9291	employed	_
56-11	9292-9293	a	_
56-12	9294-9298	full	_
56-13	9299-9308	factorial	_
56-14	9309-9317	analysis	_
56-15	9318-9319	.	_

57-1	9320-9331	Independent	_
57-2	9332-9341	variables	_
57-3	9342-9346	were	_
57-4	9347-9355	included	_
57-5	9356-9359	for	_
57-6	9360-9365	group	_
57-7	9366-9367	(	_
57-8	9368-9370	HC	_
57-9	9371-9373	vs	_
57-10	9374-9376	SZ	_
57-11	9377-9378	)	_
57-12	9379-9380	,	_
57-13	9381-9385	time	_
57-14	9386-9387	(	_
57-15	9388-9408	unmedicated/baseline	_
57-16	9409-9411	vs	_
57-17	9412-9416	week	_
57-18	9417-9420	six	_
57-19	9421-9422	)	_
57-20	9423-9426	and	_
57-21	9427-9430	the	_
57-22	9431-9442	interaction	_
57-23	9443-9445	of	_
57-24	9446-9451	group	_
57-25	9452-9455	and	_
57-26	9456-9460	time	_
57-27	9461-9462	(	_
57-28	9463-9468	group	_
57-29	9469-9470	×	_
57-30	9471-9475	time	_
57-31	9476-9477	)	_
57-32	9478-9479	.	_

58-1	9480-9488	Contrast	_
58-2	9489-9495	images	_
58-3	9496-9500	were	_
58-4	9501-9510	generated	_
58-5	9511-9514	for	_
58-6	9515-9518	the	_
58-7	9519-9524	group	_
58-8	9525-9526	×	_
58-9	9527-9531	time	_
58-10	9532-9543	interaction	_
58-11	9544-9545	.	_

59-1	9546-9548	To	_
59-2	9549-9558	correctly	_
59-3	9559-9568	partition	_
59-4	9569-9572	the	_
59-5	9573-9581	variance	_
59-6	9582-9585	for	_
59-7	9586-9591	valid	_
59-8	9592-9606	interpretation	_
59-9	9607-9609	of	_
59-10	9610-9613	the	_
59-11	9614-9618	main	_
59-12	9619-9626	effects	_
59-13	9627-9629	of	_
59-14	9630-9635	group	_
59-15	9636-9639	and	_
59-16	9640-9644	time	_
59-17	9645-9656	independent	_
59-18	9657-9663	sample	_
59-19	9664-9671	t-tests	_
59-20	9672-9675	and	_
59-21	9676-9689	paired-sample	_
59-22	9690-9697	t-tests	_
59-23	9698-9702	were	_
59-24	9703-9706	run	_
59-25	9707-9708	.	_

60-1	9709-9711	In	_
60-2	9712-9715	the	_
60-3	9716-9724	presence	_
60-4	9725-9727	of	_
60-5	9728-9729	a	_
60-6	9730-9741	significant	_
60-7	9742-9747	group	_
60-8	9748-9749	×	_
60-9	9750-9754	time	_
60-10	9755-9766	interaction	_
60-11	9767-9768	,	_
60-12	9769-9779	functional	_
60-13	9780-9792	connectivity	_
60-14	9793-9799	values	_
60-15	9800-9804	were	_
60-16	9805-9814	extracted	_
60-17	9815-9817	at	_
60-18	9818-9821	the	_
60-19	9822-9832	individual	_
60-20	9833-9838	level	_
60-21	9839-9844	using	_
60-22	9845-9848	REX	_
60-23	9849-9850	.	_

61-1	9851-9854	For	_
61-2	9855-9859	each	_
61-3	9860-9865	group	_
61-4	9866-9867	,	_
61-5	9868-9870	we	_
61-6	9871-9881	correlated	_
61-7	9882-9885	the	_
61-8	9886-9892	change	_
61-9	9893-9895	in	_
61-10	9896-9906	functional	_
61-11	9907-9919	connectivity	_
61-12	9920-9927	between	_
61-13	9928-9935	regions	_
61-14	9936-9946	identified	_
61-15	9947-9949	in	_
61-16	9950-9953	the	_
61-17	9954-9959	group	_
61-18	9960-9961	×	_
61-19	9962-9966	time	_
61-20	9967-9978	interaction	_
61-21	9979-9982	and	_
61-22	9983-9991	compared	_
61-23	9992-9994	R2	_
61-24	9995-10001	values	_
61-25	10002-10009	between	_
61-26	10010-10016	groups	_
61-27	10017-10018	.	_

62-1	10019-10025	Linear	_
62-2	10026-10036	regression	_
62-3	10037-10040	was	_
62-4	10041-10045	used	_
62-5	10046-10048	to	_
62-6	10049-10058	determine	_
62-7	10059-10066	whether	_
62-8	10067-10077	functional	_
62-9	10078-10090	connectivity	_
62-10	10091-10093	at	_
62-11	10094-10102	baseline	_
62-12	10103-10105	in	_
62-13	10106-10117	unmedicated	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
62-14	10118-10120	SZ	_
62-15	10121-10124	was	_
62-16	10125-10132	related	_
62-17	10133-10135	to	_
62-18	10136-10146	subsequent	_
62-19	10147-10156	treatment	_
62-20	10157-10165	response	_
62-21	10166-10169	and	_
62-22	10170-10172	to	_
62-23	10173-10182	determine	_
62-24	10183-10190	whether	_
62-25	10191-10198	changes	_
62-26	10199-10201	in	_
62-27	10202-10212	functional	_
62-28	10213-10225	connectivity	_
62-29	10226-10230	over	_
62-30	10231-10234	the	_
62-31	10235-10241	course	_
62-32	10242-10244	of	_
62-33	10245-10246	6	_
62-34	10247-10252	weeks	_
62-35	10253-10257	were	_
62-36	10258-10265	related	_
62-37	10266-10268	to	_
62-38	10269-10278	treatment	_
62-39	10279-10287	response	_
62-40	10288-10289	.	_

63-1	10290-10293	For	_
63-2	10294-10297	the	_
63-3	10298-10304	latter	_
63-4	10305-10306	,	_
63-5	10307-10315	contrast	_
63-6	10316-10322	images	_
63-7	10323-10327	were	_
63-8	10328-10335	created	_
63-9	10336-10341	using	_
63-10	10342-10348	IMCalc	_
63-11	10349-10350	(	_
63-12	10351-10357	Stroop	_
63-13	10358-10362	week	_
63-14	10363-10364	6	_
63-15	10365-10366	–	_
63-16	10367-10373	Stroop	_
63-17	10374-10382	baseline	_
63-18	10383-10384	)	_
63-19	10385-10388	and	_
63-20	10389-10393	then	_
63-21	10394-10401	entered	_
63-22	10402-10406	into	_
63-23	10407-10410	the	_
63-24	10411-10421	regression	_
63-25	10422-10423	.	_

64-1	10424-10426	To	_
64-2	10427-10436	visualize	_
64-3	10437-10440	the	_
64-4	10441-10453	distribution	_
64-5	10454-10456	of	_
64-6	10457-10465	variance	_
64-7	10466-10476	associated	_
64-8	10477-10481	with	_
64-9	10482-10487	these	_
64-10	10488-10496	analyses	_
64-11	10497-10498	,	_
64-12	10499-10501	we	_
64-13	10502-10511	extracted	_
64-14	10512-10515	the	_
64-15	10516-10521	first	_
64-16	10522-10534	eigenvariate	_
64-17	10535-10537	of	_
64-18	10538-10541	the	_
64-19	10542-10548	effect	_
64-20	10549-10551	of	_
64-21	10552-10560	interest	_
64-22	10561-10563	in	_
64-23	10564-10571	regions	_
64-24	10572-10577	where	_
64-25	10578-10587	treatment	_
64-26	10588-10596	response	_
64-27	10597-10600	was	_
64-28	10601-10611	correlated	_
64-29	10612-10616	with	_
64-30	10617-10626	treatment	_
64-31	10627-10635	response	_
64-32	10636-10639	and	_
64-33	10640-10647	plotted	_
64-34	10648-10651	the	_
64-35	10652-10661	extracted	_
64-36	10662-10668	values	_
64-37	10669-10670	(	_
64-38	10671-10679	z-scores	_
64-39	10680-10681	)	_
64-40	10682-10689	against	_
64-41	10690-10699	treatment	_
64-42	10700-10708	response	_
64-43	10709-10710	.	_

65-1	10711-10720	Treatment	_
65-2	10721-10729	response	_
65-3	10730-10733	was	_
65-4	10734-10741	defined	_
65-5	10742-10744	as	_
65-6	10745-10748	the	_
65-7	10749-10756	percent	_
65-8	10757-10763	change	_
65-9	10764-10766	on	_
65-10	10767-10770	the	_
65-11	10771-10775	BPRS	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
65-12	10776-10785	psychosis	_
65-13	10786-10794	subscale	_
65-14	10795-10799	from	_
65-15	10800-10808	baseline	_
65-16	10809-10810	(	_
65-17	10811-10812	A	_
65-18	10813-10814	)	_
65-19	10815-10817	to	_
65-20	10818-10821	six	_
65-21	10822-10827	weeks	_
65-22	10828-10830	of	_
65-23	10831-10842	risperidone	_
65-24	10843-10844	(	_
65-25	10845-10846	B	_
65-26	10847-10848	)	_
65-27	10849-10850	:	_
65-28	10851-10859	Analyses	_
65-29	10860-10864	were	_
65-30	10865-10874	corrected	_
65-31	10875-10878	for	_
65-32	10879-10887	multiple	_
65-33	10888-10899	comparisons	_
65-34	10900-10905	using	_
65-35	10906-10929	small-volume-correction	_
65-36	10930-10931	(	_
65-37	10932-10935	SVC	_
65-38	10936-10937	)	_
65-39	10938-10940	in	_
65-40	10941-10951	accordance	_
65-41	10952-10956	with	_
65-42	10957-10965	Gaussian	_
65-43	10966-10972	random	_
65-44	10973-10978	field	_
65-45	10979-10985	theory	_
65-46	10986-10987	(	_
65-47	10988-10989	p	_
65-48	10990-10991	<	_
65-49	10992-10996	0.05	_
65-50	10997-10998	)	_
65-51	10999-11000	.	_

66-1	11001-11003	In	_
66-2	11004-11009	order	_
66-3	11010-11012	to	_
66-4	11013-11020	observe	_
66-5	11021-11031	functional	_
66-6	11032-11044	connectivity	_
66-7	11045-11047	in	_
66-8	11048-11051	the	_
66-9	11052-11059	network	_
66-10	11060-11062	of	_
66-11	11063-11071	interest	_
66-12	11072-11073	,	_
66-13	11074-11081	results	_
66-14	11082-11086	were	_
66-15	11087-11097	restricted	_
66-16	11098-11102	with	_
66-17	11103-11104	a	_
66-18	11105-11109	mask	_
66-19	11110-11120	containing	_
66-20	11121-11128	regions	_
66-21	11129-11131	of	_
66-22	11132-11135	the	_
66-23	11136-11151	fronto-striatal	_
66-24	11152-11159	network	_
66-25	11160-11161	.	_

67-1	11162-11165	The	_
67-2	11166-11181	fronto-striatal	_
67-3	11182-11189	network	_
67-4	11190-11194	mask	_
67-5	11195-11198	was	_
67-6	11199-11207	composed	_
67-7	11208-11210	of	_
67-8	11211-11214	the	_
67-9	11215-11222	putamen	_
67-10	11223-11226	and	_
67-11	11227-11234	caudate	_
67-12	11235-11239	from	_
67-13	11240-11246	IBASPM	_
67-14	11247-11250	116	_
67-15	11251-11254	and	_
67-16	11255-11263	midbrain	_
67-17	11264-11268	from	_
67-18	11269-11271	TD	_
67-19	11272-11277	lobes	_
67-20	11278-11280	as	_
67-21	11281-11285	part	_
67-22	11286-11288	of	_
67-23	11289-11292	the	_
67-24	11293-11296	WFU	_
67-25	11297-11306	pickatlas	_
67-26	11307-11308	.	_

68-1	11309-11311	An	_
68-2	11312-11317	image	_
68-3	11318-11320	of	_
68-4	11321-11324	the	_
68-5	11325-11333	composed	_
68-6	11334-11338	mask	_
68-7	11339-11341	is	_
68-8	11342-11350	provided	_
68-9	11351-11353	in	_
68-10	11354-11364	Supplement	_
68-11	11365-11368	Fig	_
68-12	11369-11370	.	_

69-1	11371-11372	1	_
69-2	11373-11374	.	_

